Potential of the TRPM7 channel as a novel therapeutic target for pulmonary arterial hypertension

Pulmonary arterial hypertension (PAH) is an intractable vascular disease characterized by a progressive increase in pulmonary vascular resistance caused by pulmonary vascular remodeling, which ultimately leads to right-sided heart failure. PAH remains incurable, despite the development of PAH-target...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Smooth Muscle Research 2022, Vol.58, pp.50-62
Main Authors: Hiraishi, Keizo, Kurahara, Lin Hai, Ishikawa, Kaori, Go, Tetsuhiko, Yokota, Naoya, Hu, Yaopeng, Fujita, Takayuki, Inoue, Ryuji, Hirano, Katsuya
Format: Article
Language:English
Subjects:
cardiovascular remodeling
Invited Review
pulmonary arterial hypertension
TRPM7
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pulmonary arterial hypertension (PAH) is an intractable vascular disease characterized by a progressive increase in pulmonary vascular resistance caused by pulmonary vascular remodeling, which ultimately leads to right-sided heart failure. PAH remains incurable, despite the development of PAH-targeted therapeutics centered on pulmonary artery relaxants. It is necessary to identify the target molecules that contribute to pulmonary artery remodeling. Transient receptor potential (TRP) channels have been suggested to modulate pulmonary artery remodeling. Our study focused on the transient receptor potential ion channel subfamily M, member 7, or the TRPM7 channel, which modulates endothelial-to-mesenchymal transition and smooth muscle proliferation in the pulmonary artery. In this review, we summarize the role and expression profile of TRPM7 channels in PAH progression and discuss TRPM7 channels as possible therapeutic targets. In addition, we discuss the therapeutic effect of a Chinese herbal medicine, Ophiocordyceps sinensis (OCS), on PAH progression, which partly involves TRPM7 inhibition.
ISSN:0916-8737
1884-8796
DOI:10.1540/jsmr.58.50